Recent Advances in Delivering Strategies of Domperidone Challenges and Opportunities

Year : 2021 | Volume : 08 | Issue : 02 | Page : 13-24
By

    M.A.K. Azad

  1. Md. Masudur Rahman

  2. Shimul Halder

  3. Eva Rahman Kabir

  1. Assistant Professor, Department of Pharmacy, BRAC University, Mohakhali, Dhaka, Bangladesh
  2. Research Scholar, Department of Pharmacy, BRAC University, Mohakhali, Dhaka, Bangladesh
  3. Associate Professor, Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh
  4. Professor, Department of Pharmacy, BRAC University, Mohakhali, Dhaka, Bangladesh

Abstract

Domperidone (DMP), a potent gastroprokinetic and antiemetic drug, exhibits poor aqueous solubility and limited oral bioavailability. Therefore, to develop oral preparations with optimized oral bioavailability, the pharmacokinetic parameters of DMP need to be controlled. The present review aimed to discuss the physicochemical characteristics of DMP causing its unfavorable oral delivery, to explore the viable oral formulation approaches, and to propose some recent formulation approaches that can mitigate the above mentioned difficulties in delivering DMP. In this study, some effective strategies in terms of pharmacokinetic behavior of DMP have been comparatively discussed. It has been recommended that, the amorphous solid dispersion approach could be more convincing from the scalability perspective along with its significant improvement in dissolution behavior and oral bioavailability. Finally, some future perspectives of these strategies have also been addressed to facilitate efficient formulation development.

Keywords: Domperidone; solubility; drug delivery strategy; pharmacokinetic, bioavailability.

[This article belongs to Trends in Drug Delivery(tdd)]

How to cite this article: M.A.K. Azad, Md. Masudur Rahman, Shimul Halder, Eva Rahman Kabir Recent Advances in Delivering Strategies of Domperidone Challenges and Opportunities tdd 2021; 08:13-24
How to cite this URL: M.A.K. Azad, Md. Masudur Rahman, Shimul Halder, Eva Rahman Kabir Recent Advances in Delivering Strategies of Domperidone Challenges and Opportunities tdd 2021 {cited 2021 Aug 25};08:13-24. Available from: https://journals.stmjournals.com/tdd/article=2021/view=92151

Browse Figures

References

1. Vetrivel N, Praveen D, Ranadheer Chowdary P, Elan Cheziyan K, Vijey Aanandhi M. Comparison of safety and effectiveness of ondansetron and domperidone in patients with gastrointestinal problems. Drug Invent Today. 2018;10(3):343–6.
2. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6(6):571–6.
3. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, et al. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005;81(1):211–9.
4. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone: A Review of its Pharmacological Activity, Pharmacokinetics and Therapeutic Efficacy in the Symptomatic Treatment of Chronic Dyspepsia and as an Antiemetic. Drugs. 1982;24(5):360–400.
5. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: Review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm Res An Off J Am Assoc Pharm Sci. 1995;12(3):413–20.
7. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006;23(6):1144–56.
8. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm. 2011;420(1):1–10.
9. Boyd BJ, Bergström CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P, et al. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137.
10. Patel K, Prasad RK, Bajpai M. Enhancement of dissolution rate of domperidone using melt granulation technique. Der Pharm Lett. 2011;3(2):25–33.
11. Tyagi R, Dhillon V. Enhancement of Solubility and Dissolution Rate of Domperidone Using Cogrinding and Kneading Technique. J Drug Deliv Ther. 2012 Jul 15;2(4):152–4.
12. Stephen Olaribigbe Majekodunmi, Cynthia Chibuzor Uzoaganobi. Formulation of Domperidone Microspheres Using a Combination of Locally Extracted Chitosan and Hpmc as Polymers. J Chem Chem Eng. 2017;11(2):65–74.
13. Patel D, Sawant K. Self Micro-Emulsifying Drug Delivery System: Formulation Development and Biopharmaceutical Evaluation of Lipophilic Drugs. Curr Drug Deliv. 2009;6(4):419–24.
14. Prajapati BG, Patel D V. Formulation and optimization of domperidone fast dissolving tablet by wet granulation techniques using factorial design. Int J PharmTech Res. 2010;2(1):292–9.
15. Khan Sadozai S, Ahmad Chishti K, Ullah R, Hussain Z, Khan Sadozai M, Ur Rahman S, et al. Formulation development and evaluation of domperidone sustained release matrix tablets by two different methods using guar gum as a sustaining agent. World Appl Sci J. 2013;25(12):1704–12.
16. Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol Suppl. 1984;19(96):127–36.
17. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986 Sep 1;135(5):457–61.
18. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981 Jan;6(1):49–60.
19. Barone JA. Domperidone: A Peripherally Acting Dopamine 2 -Receptor Antagonist. Ann Pharmacother. 1999 Apr 28;33(4):429–40.
20. Naonori K, Hiroshi Y, Ken I, Katsumi M. A new type of a pH-independent controlled release tablet. Int J Pharm. 1991 Feb;68(1–3):255–64.
21. Thoma K, Zimmer T. Retardation of weakly basic drugs with diffusion tablets. Int J Pharm. 1990;58(3):197–202.
22. McCallum RW. Review of the Current Status of Prokinetic Agents in Gastroenterology. Am J Gastroenterol. 1985;80(12):1008–16.
23. Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol. 1983;89(1):137–41.
24. Reynolds JC, Putnam PE. Prokinetic agents. [Internet]. Vol. 21, Gastroenterology clinics of North America. 1992. 530–536 p. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1516959.
25. Washabau RJ. Prokinetic Agents. In: Canine and Feline Gastroenterology. 2012. p. 530–6. 26. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, et al. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994;268(1):417–26.
27. Barone JA. Domperidone: A peripherally acting dopamine2-receptor antagonist. Vol. 33, Annals of Pharmacotherapy. 1999. p. 429–40.
28. Corinaldesi R, Stanghellini V, Zarabini GE. The effect of domperidone on the gastric emptying of solid and liquid phases of a mixed meal in patients with dyspepsia. Curr Ther Res – Clin Exp. 1983;34(4):982–6.
29. Del Genio A, Di Martino N, Piccolo S, Maffettone V, Landolfi V, Salvatore M. The effect of domperidone on gastric emptying in reflux esophagitis: A radioisotopic study. J Nucl Med Allied Sci. 1984;28(4):251–6.
30. Baeyens R, van De Velde E, de Schepper A, Wollaert F, Reyntjens A. Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgrad Med J. 1979;55:19–23.
31. Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84(9):1069–75.
32. Maddern G, Horowitz M, Jamieson G. The effect of domperidone on oesophageal emptying in diabetic autonomic neuropathy. Br J Clin Pharmacol. 1985 Apr;19(4):441–4.
33. Weihrauch TR, Foerster Ch. F, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad Med J. 1979; 34. Brock-Utne JG, Downing JW, Dimopoulos GE, Rubin J, Moshal MG. Effect of Domperidone on Lower Esophageal Sphincter Tone in Late Pregnancy. Anesthesiology. 1980 Apr 1;52(4):321–3.
35. Sowers JR, Sharp B, McCallum RW. Effect of Domperidone, an Extracerebral Inhibitor of Dopamine Receptors, on Thyrotropin, Prolactin, Renin, Aldosterone, and 18- Hydroxycorticosterone Secretion in Man. J Clin Endocrinol Metab. 1982;54(4):869–71.
36. Brouwers JRBJ, Assies J, Wiersinga WM, Huizing G, Tytgat GN. Plasma Prolactin Levels after Acute and Subchronic Oral Administration of Domperidone and Metoclopramide: A Cross-Over Study in Healthy Volunteers. Clin Endocrinol (Oxf). 1980 May;12(5):435–40.
37. Niemegeers CJE, Schellekens KHL, Janssen PAJ. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther. 1980;244(1):130–40.
38. Degli Uberti EC, Trasforini GC, Margutti AR, Sammaroli SR, Fersini C, Pansini R. Plasma aldosterone response to domperidone, an extracerebral dopamine receptor blocker, in normal subjects. Panminerva Med. 1981;23(3):183–6.
39. Huang Y ‐C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJP. Pharmacokinetics and Dose Proportionality of Domperidone in Healthy Volunteers. J Clin Pharmacol. 1986;26(8):628–32.
40. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70.
41. Michiels M, Hendriks R, Heykants J. On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur J Drug Metab Pharmacokinet. 1981;6(1):37–48.
42. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70.
43. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981;6(1):49–60.
44. Simard C, Michaude V, Gibbs B, Massé R, Lessardu É, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34(11–12):1013– 23.
45. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4- tetrahydro- 6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, a. J Pharmacol Exp Ther. 2004;310(2):703–9.
46. Youssef AS, Parkman HP, Nagar S. Drug-drug interactions in pharmacologic management of gastroparesis. Neurogastroenterol Motil. 2015 Nov;27(11):1528–41.
47. Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica. 2009 Oct 3;39(10):749–56.
48. Lim HK, Duczak N, Brougham L, Elliot M, Patel K, Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos. 2005;33(8):1211–9.
49. Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica. 2014;44(9):792–803.
50. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: A randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–21.
51. Alhumayyd MS, Bukhari IA, Almotrefi AA. Effect of piperine, amajor component of black pepper, on the pharmacokinetics of domperidone in rats. J Physiol Pharmacol. 2014;65(6):785–9.
52. Harris RZ, Jang GR, Tsunoda S. Dietary Effects on Drug Metabolism and Transport. Vol. 42, Clinical Pharmacokinetics. 2003. p. 1071–88.
53. Bamburowicz-Klimkowska M, Zywiec K, Potentas A, Szutowski M. Impact of the changes in P- glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Reports. 2007;59(6):752–6.
54. Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(4):182–4.
55. Shindler J, Finnerty G, Towlson K, Dolan A, Davies C, Parkes J. Domperidone and levodopa in Parkinson’s disease. Br J Clin Pharmacol. 1984;18(6):959–62.
56. Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: An in vitro analysis. Xenobiotica. 2009;39(10):749–56.
57. Jain P, Goel A, Sharma S, Parmar M. Solubility Enhancement Techniques with Special Emphasis on Hydrotrophy. Int J Pharma Prof Res. 2010;1(1):34–45.
58. Patil HG, Tiwari R V., Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm. 2016;42(6):906–15.
59. Sutradhar KB, Akhter DT, Uddin R. Formulation and evaluation of taste masked oral dispersible tablets of Domperidone using sublimation method. Int J Pharm Pharm Sci. 2012;4(2):727–32.
60. Aboutaleb AE, Abdel-Rahman SI, Ahmed MO, Younis MA. Improvement of domperidone solubility and dissolution rate by dispersion in various hydrophilic carriers. J Appl Pharm Sci. 2016;6(7):133–9.
61. Nagpal M, Kaur L, Chander J, Sharma P. Dissolution Enhancement of Domperidone Fast Disintegrating Tablet Using Modified Locust Bean Gum by Solid Dispersion Technique. J Pharm Technol Res Manag. 2016;4(1):1–11.
62. Patel D, Patel S, Patel C. Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion. Int J Pharm Investig. 2014;4(4):174–82.
63. Palem CR, Kumar Battu S, Maddineni S, Gannu R, Repka MA, Yamsani MR. Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. Pharm Dev Technol. 2013 Feb 13;18(1):186–95.
64. Thapa P, Thapa R, Budhathoki U, Thapa P. Solubility Enhancement of Domperidone Fast Disintegrating Tablet Using Hydroxypropyl-β-Cyclodextrin by Inclusion Complexation Technique. Pharmacol & Pharm. 2014;5(3):238–49.
65. Khan W, Siddique NF, Siddiqui J, Hussain Z, Farooqui S. Formulation and Evaluation of Domperidone Sustained Release Tablet. Res J Pharm Technol. 2018;11(12):5599–610.
66. Enteshari S, Varshosaz J. Solubility Enhancement of Domperidone by Solvent Change In situ Micronization Technique. Adv Biomed Res. 2018;7(1):1–8.
67. Zayed GM, Rasoul SA El, Ibrahim MA, Saddik MS, Alshora DH. In vitro and in vivo characterization of domperidone-loaded fast dissolving buccal films. Saudi Pharm J. 2020;28(3):266–73.
68. Kibria G, Akhter A, Ariful Islam K. Formulation and evaluation of domperidone pellets prepared by powder layering technology. Asian J Pharm. 2010;4(1):41–7.
69. Ramu A, Vidyadhara S, Devanna N, Naidu U, Kalyani P. Formulation and evaluation of irbesartan fast dissolving tablets. Asian J Pharm. 2013;7(2):61–7.


Regular Issue Subscription Article
Volume 08
Issue 02
Received May 27, 2021
Accepted August 10, 2021
Published August 25, 2021